NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT05696717,Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy,https://clinicaltrials.gov/study/NCT05696717,CYPRESS,RECRUITING,"This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This study includes 4 periods: Screening, open label, randomized withdrawal, and long-term treatment extension (LTE).",NO,Symptomatic Neurogenic Orthostatic Hypotension|MSA - Multiple System Atrophy,DRUG: Ampreloxetine|DRUG: Placebo,"Change in OHSA composite score at Week 8 during the double-blind RW period, Score change from baseline on the composite of Questions 1 - 6 of the Orthostatic Hypotension Symptom Assessment (OHSA)., 8-week randomized withdrawal period (Week 12 to Week 20)","Change from baseline in OHDAS item 1 (activities that require standing for a short time) at Week 8 post randomization, Orthostatic Hypotension Daily Activities Scale (OHDAS) is an assessment of how low blood pressure symptoms affect daily life., 8-week randomized withdrawal period (Week 12 to Week 20)|Change from baseline in OHDAS item 3 (activities that require walking for a short time) at Week 8 post randomization, Orthostatic Hypotension Daily Activities Scale (OHDAS) is an assessment of how low blood pressure symptoms affect daily life., 8-week randomized withdrawal period (Week 12 to Week 20)",,Theravance Biopharma,,ALL,"ADULT, OLDER_ADULT",PHASE3,102,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-003903-14,2023-06-27,2024-12,2027-01,2023-01-25,,2024-12-27,"Movement Disorders Center of Arizona, Scottsdale, Arizona, 85258, United States|The Parkinson's and Movement Disorder Institute, Fountain Valley, California, 92708, United States|UC San Diego Movement Disorder Center, La Jolla, California, 92037, United States|Stanford Neuroscience Health Center, Palo Alto, California, 94304, United States|Medstar Georgetown University Hospital, Washington DC, District of Columbia, 20007, United States|Parkinson's Disease And Movement Disorders Center of Boca Raton, Boca Raton, Florida, 33486, United States|SFM Clinical Research, LLC, Boca Raton, Florida, 33487, United States|Aqualane Clinical Research, Naples, Florida, 34105, United States|Neurostudies, Inc, Port Charlotte, Florida, 33952, United States|University of South Florida Ataxia Research Center, Tampa, Florida, 33612, United States|Theravance Biopharma Investigative Site, Atlanta, Georgia, 30329, United States|Hawaii Pacific Neuroscience, Honolulu, Hawaii, 96817, United States|Rush University Medical Center, Chicago, Illinois, 60612, United States|Northshore University Health System, Glenview, Illinois, 60026-1339, United States|University of Kansas Medical Center Research Institute, Inc., Kansas City, Kansas, 66160, United States|TBPH Investigative Site, Boston, Massachusetts, 02114, United States|Massachusetts Chan Medical School, Worcester, Massachusetts, 01655, United States|Quest Research Institute, Farmington Hills, Michigan, 48334, United States|NYU Langone Health NYU Dysautonomia Center, New York, New York, 10016, United States|The Neurological Institute at Columbia University Medical Center, New York, New York, 10032, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, 45219, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|Theravance Biopharma Investigative Site, Houston, Texas, 77030, United States|INEBA Instituto Neurociencias Buenos Aires, Caba, C1192AAW, Argentina|Hospital General de Agudos Jose Maria Ramos Mejía, Caba, C1221ADC, Argentina|Hospital Británico de Buenos Aires, Caba, C1280AEB, Argentina|Instituto Fleni, Caba, C1428AQK, Argentina|Médico/Hospital de la Policía Federal Churruca Visca, Caba, C1437JCP, Argentina|Fundación Scherbovsky, Mendoza, M5500, Argentina|Theravance Biopharma Investigative Site, Clayton, Victoria, 3168, Australia|Theravance Biopharma Investigative Site, Melbourne, Victoria, 3168, Australia|Theravance Biopharma Investigative Site, Parkville, Victoria, 3050, Australia|Medical University of Innsbruck, Innsbruck, A-6020, Austria|Universitatsklinikum Tulln, Tulln, Austria|UZA - Antwerp University Hospital - Department of Neurology, Edegem, Belgium|Instituto de Neurologia de Curitiba S\C LTDA, Curitiba, PR, 81210-310, Brazil|Hospital de Clínicas - Universidade Federal de Minas Gerais (HC - UFMG), Belo Horizonte, 30130-100, Brazil|Centro de Pesquisa Clínica (CPC) do Hospital das Clínicas de Porto Alegre (HCPA), Porto Alegre, 90035-903, Brazil|Hospital São Lucas - PUCRS, Porto Alegre, 90610-000, Brazil|Hospital da Bahia, Salvador, 41810-011, Brazil|University of Calgary - Health Sciences Centre, Calgary, Alberta, T2N 4Z6, Canada|Bispebjerg Hospital, Copenhagen, 2400-NV, Denmark|Astra Clinic (Clinic4U), Tallinn, 11315, Estonia|Tartu University Hospital, Tartu, 30029, Estonia|Theravance Biopharma Investigative Site, Nimes, Occitanie, Cedex 9, France|Centre Hospitalier Universitaire de Bordeaux Health, Bordeaux, 33076, France|Centre d'Investigation Clinique Hôpital Pierre Paul Rique, Toulouse, 31059 Cedex, France|Praxis Dr. Oehlwein, Outpatient Clinic, Gera, Thueringen, 07551, Germany|Charité - Universitätsmedizin Berlin- Campus Mitte, Berlin, 10117, Germany|Charite Universitaetsmedizin Berlin, Berlin, 12203, Germany|Semmelweis Egyetem, Budapest, 1085, Hungary|Theravance Biopharma Investigative Site, Tel Aviv, 64239, Israel|IRCCS Istituto de Scienze Neurologiche di Bologna (ISNB), Bologna, 40139, Italy|Parkinson's Centre of Ospedale CTO, Milano, 20126, Italy|Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Rome, 00133, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, 00168, Italy|AOU San Giovanni di Dio e Ruggi d'Aragona, Salerno, Salerno, 84131, Italy|Azienda Ospedaliera Santa Maria di Terni, Terni, I-05100, Italy|Santa Chiara Hospital, Trento, 38122, Italy|Pia Fond. Cardinale Giovanni Panico Azienda Ospedaliera, Tricase, 73039, Italy|Theravance Biopharma Investigative Site, Grafton, Auckland, 1023, New Zealand|Theravance Biopharma Investigative Site, Christchurch, 8011, New Zealand|Neurocentrum-Miwomed, Gdańsk, 80-207, Poland|Neuro-Care Sp. z o.o. Sp. Komandytowa, Katowice, 40-749, Poland|Krakowska Akademia Neurologii Sp.zo.o., Kraków, 31-505, Poland|Instytut Zdrowia dr Boczarska-Jedynak Sp. z o.o., Sp.k., Oświęcim, 32-600, Poland|CNS-Campus Neurologico Senior, Torres Vedras, 2560-280, Portugal|Fundació Assistencial Mutua de Terrassa, Terrassa, Barcelona, 08222, Spain|Hospital Germans Trias i Pujol, Department of Neurology, Barakaldo, Bizkaia, 48903, Spain|Instituto Investigación Sanitaria Biocruces, Barakaldo, Bizkaia, 48903, Spain|Hospital Universitario de La Princesa, Madrid, 28006, Spain|Hospital Universitario Infante Sofia Paseo Europa, Madrid, 28702, Spain|Theravance Biopharma Investigative Site, Taipei City, 106, Taiwan|University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2GW, United Kingdom|Barts Health, London, EC1M 6BQ, United Kingdom|Autonomic Unit, National Hospital for Neurology & Neurosurgery, London, WC1N 3BG, United Kingdom|Salford Royal Hospital, Salford, M6 8HD, United Kingdom",
